A seismic shift in pediatric medical care has arrived with the FDA’s approval of Ryoncil (remestemcel-L-rknd), a ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

This phase can last months, requiring various protective measures to prevent complications. Graft-versus-host disease remains ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...

Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...